Bain Capital, an investment firm, is reportedly in discussions to acquire Mitsubishi Tanabe Pharma Corp., a subsidiary of Mitsubishi Chemical Group of Japan. According to sources familiar with the matter, these negotiations are in their final stages, and the transaction could potentially be valued at over 500 billion Japanese yen, equivalent to about $3.2 billion.
Previously, it had been reported by Nikkei that Mitsubishi Chemical had granted the U.S. investment fund exclusive negotiation rights for acquiring its pharmaceutical division. However, in response to this report, Mitsubishi Chemical clarified that the information had not been officially released by the company.
In an official statement, the company mentioned, "We are continuously reviewing the optimal business portfolio of the entire group for all of our enterprises, including the Pharma sector, and are actively considering portfolio restructuring with all possibilities, including divestiture. We will promptly communicate any relevant developments."
As of Tuesday's close of regular trading in Japan, Mitsubishi Chemical's shares concluded at 792 yen, marking a 1.85% increase.
